Triptorelin
GnRH agonist approved for prostate cancer and precocious puberty — suppression, not stimulation.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About Triptorelin
Triptorelin is a synthetic GnRH decapeptide analogue approved in two very different depot products: Trelstar, for the palliative treatment of advanced prostate cancer, and Triptodur, for central precocious puberty in children aged two and older. Both work by sustained receptor occupancy that shuts the hypothalamic-pituitary-gonadal axis down. Before it suppresses, it stimulates: serum testosterone rises, peaking around day 3, and only falls to castrate levels by weeks 3–4. That initial flare is a documented clinical hazard rather than a curiosity — the label warns it can worsen prostate cancer signs and symptoms, including spinal cord compression and urinary tract obstruction. The research market often uses a single small dose for the opposite purpose, to provoke an LH surge and restart the axis. That inverts the approved mechanism, is not what either product was studied for, and is not supported by the trial data behind them.
Key Benefits
- FDA-approved in two indications with substantial trial evidence
- Reliable, sustained suppression of the HPG axis
- Long-acting depot formulations dosed every 4 to 24 weeks
- Well-characterised pharmacology as a GnRH agonist
Set a goal (top of the page) to see how Triptorelin scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Initial testosterone flare peaking around day 3 — can worsen prostate cancer, causing spinal cord compression or urinary obstruction
- Hot flushes
- Reduced libido and erectile dysfunction
- Bone mineral density loss with prolonged use
- Injection site pain
- Mood changes and depression
- Hyperglycaemia and reduced glucose tolerance
Legal & Regulatory Status
Prescription only. FDA-approved as Trelstar (palliative treatment of advanced prostate cancer) and Triptodur (central precocious puberty, ages 2+). Both are clinician-administered depot products; neither approval covers axis-restart or fertility-trigger use. WADA-prohibited.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- TRIPTODUR (triptorelin) — FDA label, central precocious puberty (DailyMed)
- TRELSTAR (triptorelin) full prescribing information — flare warning, testosterone timecourse (FDA)
- Triptorelin (Triptodur) for central precocious puberty — review (PMID 29294465)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
Prices at quality-checked sources · as of August 2026 (8 days ago)
- 1mg $73.17
Observed on each vendor’s public listing — see how these sources are vetted. Peptide Concierge doesn’t sell peptides and isn’t affiliated with any vendor; confirm current pricing at the source.
Builds a working set shared across the stack builder, calculator, scheduler and compare.